March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Vun-Sin Lim: 10 Most Cited 2024 Articles in the Journal of Thoracic Oncology
Mar 6, 2025, 18:38

Vun-Sin Lim: 10 Most Cited 2024 Articles in the Journal of Thoracic Oncology

Vun-Sin Lim, Managing Editor of the Journal of Thoracic Oncology, shared a post on LinkedIn:

“Top 10 Most Cited 2024 Articles in the Journal of Thoracic Oncology.

1. The IASLC Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer

Authors: Huang J, Osarogiagbon RU, Giroux DJ, et al.

2024 Citations: 38

2. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer

Authors: Rami-Porta R, Nishimura KK, Giroux DJ, et al.

2024 Citations: 37

3. Rheumatoid Arthritis and Risk of Lung Cancer: A Nationwide Cohort Study

Authors: Cho MH, Cho JH, Eun Y, et al.

2024 Citations: 27

4. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer

Authors: Van Schil PE, Asamura H, Nishimura KK, et al.

2024 Citations: 23

5. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer

Authors: Stockhammer P, Grant M, Wurtz A, et al.

2024 Citations: 16

6. The IASLC Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer

Authors: Fong KM, Rosenthal A, Giroux DJ, et al.

2024 Citations: 16

7. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer

Authors: Bischoff P, Reck M, Overbeck T, et al.

2024 Citations: 16

8. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

Authors: Cheng Y, Fan Y, Zhao Y, et al.

2024 Citations: 15

9. The IASLC Staging Project for Lung Cancer: Recommendation to Introduce Spread Through Air Spaces as a Histologic Descriptor in the Ninth Edition of the TNM Classification of Lung Cancer. Analysis of 4061 Pathologic Stage I NSCLC

Authors: Travis WD, Eisele M, Nishimura KK, et al.

2024 Citations: 15

10. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

Authors: Nassar A.H., Kim S.Y., Aredo J.V., et al.

2024 Citations: 15.”

More posts featuring Vun-Sin Lim.